93 Views | 70 Downloads
B.D., K.Z., D.M.G., S.L.G., K.M., M.A., J.L., V.D.G., J.K., D.E., and J.Y. performed and analyzed experiments. M.B., V.S., and E.G. provided conceptualization and input for the work. B.D., K.Z., D.M.G., R.T., and R.F.S. wrote the original manuscript. R.F.S. and R.T. conceptualized the experiments. All authors reviewed and edited the manuscript.
R.F.S. is the inventor of the use of baricitinib for coronavirus infections and receives royalties from Eli Lilly. His conflict of interest has been reviewed and approved by Emory University. All other authors have declared that no conflict of interest exists. Contents within this manuscript are included in patent USPTO 10670594.
This study was supported by NSF EAGER award 2032273 (to R.T., R.F.S., and K.Z.) and a Woodruff Health Science Center COVID-19 CURE award (to R.T., R.F.S., K.Z., M.B., and V.S.). R.F.S. is also funded in part by NIH grant R01MH116695. We thank Dr. Matt Frieman (University of Maryland) for sharing primer sequences targeting the N-subgenome of SARS-CoV-2. We thank Dalia Gulick, Naima Djeddar, and Gregory Gibson (Georgia Tech) for assisting with multiplexed qRT-PCR. Research reported in this publication was supported in part by the Pediatrics/Winship Flow Cytometry Core of Winship Cancer Institute of Emory University, Children's Healthcare of Atlanta. The graphical abstract was generated in Biorender. SARS-CoV-2 isolate USA-WA1/2020 was obtained from BEI Resources, Manassas, VA.
© 2022 The Author(s)